To qualify for fast tracking, a nanotechnology product typically must demonstrate significant potential to address unmet medical needs or offer substantial benefits over existing alternatives. This involves rigorous preliminary data on safety, efficacy, and toxicology. The applicant must also provide a comprehensive risk assessment and mitigation strategy.
